Shao Feng, Hu Xiao-Ling, Liu Xin, Shan Mang-Ting
Phase I Clinical Trial Unit, the First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, PR China.
Department of Drug Metabolism & Pharmacokinetics, Jiangsu Simcere Pharmaceutical R&D Co Ltd, Nanjing 210042, PR China.
J Chromatogr Sci. 2017 Jul 1;55(6):595-602. doi: 10.1093/chromsci/bmx012.
The objective of this study was to investigate the stability of edaravone in dog plasma by using an added antioxidant stabilizer, with an ultimate goal of developing and validating a sensitive, reliable and robust LC-MS-MS method for determination of edaravone in plasma samples. Edaravone was unstable in plasma, but it presented a good stability performance in the plasma with sodium metabisulfite (SMB), an effective antioxidant. The blood sample was collected in the heparinized eppendorf tube containing SMB and plasma sample was deproteinized using acetonitrile containing 20 ng/mL of phenacetin (Internal standard). The chromatographic separation was performed on a Zorbax Extend-C18 analytical column (2.1 mm × 150 mm I.D., particle size 3.5 µm, Agilent Technologies, USA). The mobile phase consisted of 0.1% formic acid in water (v/v) and methanol, and gradient elution was used. The analyte detection was performed on a triple quadrupole tandem mass spectrometer equipped with positive-ion electrospray ionization by multiple reaction ion monitoring mode of the transitions at m/z [M + H]+ 175.1 → 77.1 for edaravone, and m/z [M + H]+ 180.2 → 110.0 for phenacetin. The linearity of this method was within the concentration range of 10-1000 ng/mL for edaravone in dog plasma. The lower limit of quantification was 10 ng/mL. The relative standard deviations of intra- and inter-precision were <10%. This method was successfully employed in the pharmacokinetics evaluation of edaravone in beagle dogs after intravenous administration.
本研究的目的是通过使用添加的抗氧化稳定剂来研究依达拉奉在犬血浆中的稳定性,最终目标是开发并验证一种灵敏、可靠且稳健的液相色谱-串联质谱法,用于测定血浆样品中的依达拉奉。依达拉奉在血浆中不稳定,但在含有有效抗氧化剂焦亚硫酸钠(SMB)的血浆中表现出良好的稳定性。血样采集于含有SMB的肝素化微量离心管中,血浆样品使用含有20 ng/mL非那西丁(内标)的乙腈进行脱蛋白处理。色谱分离在Zorbax Extend-C18分析柱(内径2.1 mm×150 mm,粒径3.5 µm,美国安捷伦科技公司)上进行。流动相由0.1%甲酸水溶液(v/v)和甲醇组成,并采用梯度洗脱。在配备正离子电喷雾电离的三重四极杆串联质谱仪上,通过多反应离子监测模式对分析物进行检测,依达拉奉的跃迁为m/z [M + H]+ 175.1 → 77.1,非那西丁的跃迁为m/z [M + H]+ 180.2 → 110.0。该方法在犬血浆中依达拉奉的浓度范围为10 - 1000 ng/mL内呈线性。定量下限为10 ng/mL。批内和批间精密度的相对标准偏差均<10%。该方法成功应用于比格犬静脉注射依达拉奉后的药代动力学评价。